Forecast

There is no analyst data available for this company.

News Go to news feed

SYNBIOTIC SE: subsidiary Hempro International applies for preliminary insolvency proceedings

Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » More on finanzen.net
SynBiotic share plunges almost 20% after US cannabis reclassification

The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » More on finanzen.net
Synbiotic shares more than double since Friday after anchor investor steps in

Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, SynBiotic has already paid 0,30€ in dividends. The last payout was in July 2022.

Financials

In the last year, SynBiotic had revenue of 3.86m€ and net profit of −10.63m€

(EUR)	2023	YoY
Revenue	+3.86m	52,71%
Gross profit	+1.51m	57,83%
Net profit	−10.63m	56,36%
EBITDA	−7.12m	4,85%

Fundamentals

Metric	Value
Market capitalization	+3.45m€
Number of shares	4.75m
52-week high/low	+3,85€ - +0,50€
Dividends	No
Beta	0,68
P/E ratio	−0,32
PEG ratio	0,00
P/B ratio	+0,22
P/S ratio	+0,89

Company profile

SynBiotic SE beschäftigt sich mit der Entwicklung von Medikamenten und rezeptfreien Wellness-Produkten auf der Basis von Cannabinoiden. Das Unternehmen konzentriert sich auf die synthetische Herstellung von Cannabinoiden, die Entwicklung von Medikamenten, Nahrungsergänzungsmitteln und kosmetischen Produkten. Das Unternehmen war früher als Ledgertech SE bekannt und änderte seinen Namen in Ledgertech SE. SynBiotic SE hat seinen Sitz in München, Deutschland.